top of page
  • Amazon
  • Youtube
  • TikTok
  • Facebook
  • Instagram
Copy of kindle cover.jpg

DECODING GLP-1

An On The Pen Book

SPECIAL PRICING NOW THROUGHT CHRISTMAS!!!

Writer's pictureDave Knapp

Zepound and Mounjaro Shortage: JUDGE MAKES SHOCKING MOVE

UPDATE [January 6, 2025]: Court Grants Eli Lilly’s Motion to Join OFA vs. FDA Case



In a significant development, the court has officially allowed Eli Lilly to join the ongoing lawsuit between the Outsourcing Facilities Association (OFA) and the FDA. While the OFA initially opposed Lilly’s involvement, they later withdrew their objection, and the court agreed that Lilly’s participation is justified.


WATCH THE LIVESTREAM


Although this decision resolves one major issue, the court is keeping the hearing scheduled for January 10, 2025, to address two critical points:


  1. FDA Document Disputes: The court anticipates disagreements between the parties over how confidential FDA documents will be shared with the OFA. These documents are key to shaping the next steps in the case.

  2. Combining Legal Issues: The court is considering turning the OFA’s planned request for a preliminary injunction into a motion for summary judgment. If this happens, the court could potentially decide the entire case sooner than later, based on the law, without the need for a full trial.


The January 10 hearing will focus on ironing out the schedule for sharing documents and discussing whether the case should move straight to a summary judgment. This could accelerate the lawsuit’s resolution but will require all parties to come fully prepared for these discussions.


Stay tuned to OnThePen.com for more updates and in-depth analysis on the latest developments in weight loss and diabetes treatments. Sharing this article is a powerful form of advocacy that brings us closer to our goal of educating the masses and reducing the stigma of obesity. If you found this article insightful, please share it within your networks, especially in Facebook groups and Reddit forums dedicated to GLP-1 medications and diabetes management. Together, we can make a difference.


For context, On The Pen is a patient centric movement with the goal of providing people living with the chronic diseases of obesity and type 2 diabetes with information and resources to make more competent and confident decisions with their medical team. Sing up for email alerts at the bottom of the page and never miss an update!

bottom of page